Jingli Hao

1.6k total citations
22 papers, 1.3k citations indexed

About

Jingli Hao is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jingli Hao has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Jingli Hao's work include Prostate Cancer Treatment and Research (9 papers), Cancer Cells and Metastasis (6 papers) and Glycosylation and Glycoproteins Research (3 papers). Jingli Hao is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Cancer Cells and Metastasis (6 papers) and Glycosylation and Glycoproteins Research (3 papers). Jingli Hao collaborates with scholars based in Australia, China and India. Jingli Hao's co-authors include Yong Li, Peter Graham, Lei Chang, Jie Ni, Joseph Bucci, Paul Cozzi, John H. Kearsley, Julia Beretov, Wei Duan and Weiwei Xiao and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Jingli Hao

22 papers receiving 1.3k citations

Peers

Jingli Hao

ONCOL

PRM

IMMUN

Shou‐Ching Tang United States

Xiaodong Tan China

Su Yeon Lee South Korea

Shibu Thomas United States

Dongwei Zhang United States

Ángel Guerrero‐Zotano Spain

Lynn Kirkpatrick United States

Sheng-Chieh Hsu Taiwan

Patrick T. Grogan United States

Hyun Min Jeon South Korea

Shou‐Ching Tang United States

Jingli Hao

1.3k ×1.5

504 ×1.1

542 ×1.3

ONCOL

230 ×0.8

PRM

175 ×1.4

IMMUN

Citations per year, relative to Jingli Hao Jingli Hao (= 1×) peers Shou‐Ching Tang

Countries citing papers authored by Jingli Hao

Since Specialization

Citations

This map shows the geographic impact of Jingli Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingli Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingli Hao more than expected).

Fields of papers citing papers by Jingli Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingli Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingli Hao. The network helps show where Jingli Hao may publish in the future.

Co-authorship network of co-authors of Jingli Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Jingli Hao. A scholar is included among the top collaborators of Jingli Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingli Hao. Jingli Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hao, Jingli, et al.. (2021). Automatic Tracking System of LEO Satellite Based on SGP4. 192–199. 1 indexed citations

Ni, Jie, Julia Beretov, Valerie C. Wasinger, et al.. (2017). Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. Scientific Reports. 7(1). 41834–41834. 56 indexed citations

Ni, Jie, Paul Cozzi, Tzong‐Tyng Hung, et al.. (2016). Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique. Translational Oncology. 9(1). 41–45. 18 indexed citations

Deng, Junli, Li Wang, Hongmin Chen, et al.. (2016). Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget. 7(34). 55771–55788. 88 indexed citations

Chang, Lei, Peter Graham, Jie Ni, et al.. (2015). Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical Reviews in Oncology/Hematology. 96(3). 507–517. 151 indexed citations

Chang, Lei, Peter Graham, Jingli Hao, et al.. (2015). Proteomics discovery of radioresistant cancer biomarkers for radiotherapy. Cancer Letters. 369(2). 289–297. 21 indexed citations

Chang, Lei, Peter Graham, Jingli Hao, et al.. (2015). Cancer stem cells and signaling pathways in radioresistance. Oncotarget. 7(10). 11002–11017. 94 indexed citations

Ni, Jie, Paul Cozzi, Jingli Hao, et al.. (2014). Cancer Stem Cells in Prostate Cancer Chemoresistance. Current Cancer Drug Targets. 14(3). 225–240. 50 indexed citations

Chang, Lei, Peter Graham, Jingli Hao, et al.. (2014). Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer and Metastasis Reviews. 33(2-3). 469–496. 103 indexed citations

10.

Chang, Lei, Peter Graham, Jingli Hao, et al.. (2014). PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death and Disease. 5(10). e1437–e1437. 261 indexed citations

11.

Ni, Jie, Paul Cozzi, Jingli Hao, et al.. (2014). Abstract 4005: CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signaling pathways in vitro. Cancer Research. 74(19_Supplement). 4005–4005. 1 indexed citations

12.

Ni, Jie, Paul Cozzi, Jingli Hao, et al.. (2013). Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. The International Journal of Biochemistry & Cell Biology. 45(12). 2736–2748. 156 indexed citations

13.

Hao, Jingli, Jie Ni, Peter Graham, et al.. (2013). The CD44 Isoforms in Prostate Cancer Metastasis and Progression. 1(1). 3–14. 3 indexed citations

14.

Xiao, Weiwei, Peter Graham, Jingli Hao, et al.. (2013). Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PLoS ONE. 8(8). e74253–e74253. 29 indexed citations

15.

Wang, Li, Jingli Hao, Jie Ni, et al.. (2012). Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Letters. 329(1). 17–26. 22 indexed citations

16.

Hao, Jingli, Michele C. Madigan, Aparajita Khatri, et al.. (2012). In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147. PLoS ONE. 7(8). e40716–e40716. 70 indexed citations

17.

Wang, Li, Hongmin Chen, Mohammad H. Pourgholami, et al.. (2011). Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model. PLoS ONE. 6(9). e24405–e24405. 24 indexed citations

18.

Xiao, Weiwei, Peter Graham, Carl Power, et al.. (2011). CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clinical & Experimental Metastasis. 29(1). 1–9. 30 indexed citations

19.

Wang, Li, Hongmin Chen, Fenghua Liu, et al.. (2010). Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Letters. 300(2). 122–133. 24 indexed citations

20.

Chen, Hongmin, Li Wang, Julia Beretov, et al.. (2010). Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clinical & Experimental Metastasis. 27(8). 557–569. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact